Marinus Capex To Depreciation from 2010 to 2024
| MRNS Stock | USD 0.32 0.01 3.23% |
Capex To Depreciation | First Reported 2010-12-31 | Previous Quarter 0.21597096 | Current Value 0.21 | Quarterly Volatility 2.86570121 |
Check Marinus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marinus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 578.5 K, Interest Expense of 17.7 M or Selling General Administrative of 63.5 M, as well as many indicators such as Price To Sales Ratio of 17.91, Dividend Yield of 0.0 or PTB Ratio of 36.59. Marinus financial statements analysis is a perfect complement when working with Marinus Pharmaceuticals Valuation or Volatility modules.
Marinus | Capex To Depreciation |
Latest Marinus Pharmaceuticals' Capex To Depreciation Growth Pattern
Below is the plot of the Capex To Depreciation of Marinus Pharmaceuticals over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Marinus Pharmaceuticals' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marinus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Capex To Depreciation | 10 Years Trend |
|
Capex To Depreciation |
| Timeline |
Marinus Capex To Depreciation Regression Statistics
| Arithmetic Mean | 2.87 | |
| Geometric Mean | 1.41 | |
| Coefficient Of Variation | 100.02 | |
| Mean Deviation | 2.37 | |
| Median | 1.75 | |
| Standard Deviation | 2.87 | |
| Sample Variance | 8.21 | |
| Range | 7.928 | |
| R-Value | 0.23 | |
| Mean Square Error | 8.37 | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | 0.15 | |
| Total Sum of Squares | 114.97 |
Marinus Capex To Depreciation History
About Marinus Pharmaceuticals Financial Statements
Marinus Pharmaceuticals shareholders use historical fundamental indicators, such as Capex To Depreciation, to determine how well the company is positioned to perform in the future. Although Marinus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Marinus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marinus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capex To Depreciation | 0.22 | 0.21 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.